BIOMAT Database Logo BIOMAT Database Logo

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. 2005

P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.

BACKGROUND The K103N mutation in HIV-1 reverse transcriptase (RT) confers high-level resistance to current non-nucleoside reverse transcriptase inhibitors (NNRTI). The prevalence and resistance profile of HIV-1 with other substitutions at RT codon 103 is less well documented. METHODS K103 substitutions among over 70,000 clinical samples submitted for routine antiretroviral resistance testing at two independent centres were examined. Phenotypic resistance profiles of isolates harboring rare K103 variants in the absence of known NNRTI-associated resistance mutations were retrieved from Virco's correlative genotype/phenotype database. Genotyped samples with known treatment histories were retrieved from the British Columbia Centre for Excellence in HIV/AIDS database. Site-directed mutants containing K103 variants were constructed and phenotyped. RESULTS K103N, R and S were observed in 29, 1.8, and 0.9% of Virco isolates and in 16, 1.5 and 0.4% of British Columbia isolates. K103T/Q/H substitutions were observed only rarely (<0.2%). The prevalence of unusual codon 103 substitutions remained stable over 5 years, except K103S, which increased over fourfold in both datasets. K103R/Q-containing clinical isolates remained phenotypically susceptible to NNRTI, whereas K103S/T/H-containing isolates showed over 10-fold decreased NNRTI susceptibility. Among patients with a known treatment history, K103S/T/H were observed primarily in individuals failing NNRTI-containing regimens. Site-directed mutants confirmed decreased susceptibility to NNRTI in K103S/T/H-containing recombinants. CONCLUSIONS Variants at HIV RT codon 103 other than K103N are observed relatively rarely in clinical isolates, but K103 S, T and H confer decreased susceptibility to NNRTI. These data are relevant for interpretive genotype algorithms and in the design of assays specific to RT codon 103 mutations.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019943 Amino Acid Substitution The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties. Amino Acid Substitutions,Substitution, Amino Acid,Substitutions, Amino Acid
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).
January 2019, Chemical biology & drug design,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
January 2006, Journal of medical virology,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
November 2011, Antiviral research,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
[Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors].
January 2011, Molekuliarnaia biologiia,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
January 2005, Antiviral therapy,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors.
December 2001, Antiviral therapy,
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
April 2006, AIDS (London, England),
P Richard Harrigan, and Theresa Mo, and Brian Wynhoven, and Jennifer Hirsch, and Zabrina Brumme, and Paula McKenna, and Theresa Pattery, and Johan Vingerhoets, and Lee T Bacheler
[Resistance to non-nucleoside reverse transcriptase inhibitors].
February 2001, Enfermedades infecciosas y microbiologia clinica,
Copied contents to your clipboard!